Alnylam stock poised for strong quarter as Amvuttra launch gains traction

RBC Capital maintained its Outperform rating and $330 price target on Alnylam (ALNY) following positive survey data indicating a strong launch for Amvuttra after its label expansion for TTR-CM. A survey of cardiologists revealed high prescription rates and minimal payer resistance, with physicians projecting strong Q2 results, potentially exceeding third-party sales data showing significant monthly growth. Alnylam's revenue growth remains robust at 17.2%, and the expanded indication targets a $6B+ market growing at a 65% CAGR, reinforcing RBC's positive outlook on the stock and its path to profitability.

Analysis

RBC Capital's reiteration of an Outperform rating and a $330.00 price target for Alnylam Pharmaceuticals (ALNY) is underpinned by compelling survey data regarding its Amvuttra treatment, recently expanded for TTR-CM. A survey encompassing 35 U.S. cardiologists indicates Amvuttra's launch is significantly outperforming initial expectations, with 81% of physicians already prescribing the drug despite its pending addition to 50% of key hospital formularies, suggesting further uptake potential. Payer resistance appears minimal, as 62% of prescriptions have reportedly secured approval. Physicians surveyed project approximately 844 Amvuttra prescriptions for the second quarter, aligning with third-party data indicating a sharp rise in monthly sales from ~$35-45 million to approximately $80 million in a single recent month. This momentum supports Alnylam's robust 17.2% revenue growth over the last twelve months and its strong gross profit margin of 86%, as highlighted by InvestingPro data. The expanded indication positions Amvuttra to address a substantial market, estimated by RBC at over $6 billion and growing at a 65% CAGR. Alnylam's demonstrated market performance, with a 90% return over the past year, a comfortable current ratio of 3.04, and a clear trajectory towards profitability this year, further solidifies its favorable outlook. The recent European Commission approval for Amvuttra in TTR-CM, following U.S. and Brazil authorizations, broadens its commercial reach. This positive view is echoed by other analysts, with H.C. Wainwright setting a $500 price target and JPMorgan maintaining an Overweight rating with a $330 target, all citing Amvuttra's strong launch and market potential. The overall sentiment surrounding these developments is strongly positive, with a score of 0.85, and ALNY-specific sentiment is exceptionally high at 0.9.

Key Decisions for Investors

• Investors should consider the strong uptake and positive physician feedback for Amvuttra as key indicators of Alnylam's near-term revenue acceleration and potential to exceed earnings expectations.
• The significant market opportunity for Amvuttra in TTR-CM, valued at over $6 billion with a 65% CAGR, combined with ongoing formulary additions and minimal payer resistance, suggests sustained growth potential for Alnylam.
• Given Alnylam's robust financial health, consistent drug approval track record, anticipated profitability in the current year, and strong consensus analyst ratings, maintaining or increasing exposure to ALNY may be warranted for growth-oriented portfolios, while monitoring Q2 results for confirmation of sales trajectory.